How US Biotech Firms Can Explain AI Decisions to Regulators

The Regulatory Explainability Problem in Biotech AI

Artificial intelligence is moving faster inside biotech organizations than the regulatory frameworks governing its use. Drug discovery platforms, clinical trial matching engines, genomic interpretation tools, and manufacturing quality systems increasingly rely on models that produce recommendations without producing reasons. When a regulator asks why the model flagged that batch, or why that candidate was deprioritized, most teams have no auditable answer. The question of how US biotech firms can explain AI decisions to regulators is no longer academic — it is an operational requirement with direct consequences for approval timelines, enforcement exposure, and clinical program continuity.

Why Explainability Is a Regulatory Prerequisite, Not a Nice-to-Have

Regulators across several US agencies have been converging on the position that AI-assisted decisions in life sciences must carry traceable reasoning. The FDA's evolving guidance on artificial intelligence and machine learning in software as a medical device, along with its published principles for good machine learning practice, establish that documentation of model logic is part of the submission record. These are not hypothetical future rules — they are shaping how submissions are reviewed today.

Beyond the FDA, biotech firms working within clinical settings may encounter requirements from the Office for Human Research Protections, institutional review boards, and state-level health data statutes. Each of these bodies approaches the explainability question from a slightly different angle. The common thread is that a decision affecting a human subject or a regulated product must be reconstructable — someone must be able to explain what data went in, what the model did with it, and what output drove the downstream action.

Compliance with these layered demands cannot be retrofitted at submission time. Organizations that build explainability into their operational infrastructure from the point of model training forward create a dramatically simpler path through regulatory review. Those that treat it as a documentation exercise conducted after the fact typically discover, under review pressure, that their records cannot support the answers regulators need.

Mapping the Explainability Surface Across AI Use Cases

Before building an explainability framework, a biotech organization must first map where AI decisions are actually being made. This sounds obvious, but many organizations have AI-influenced outputs embedded in workflows that are not formally categorized as AI systems. An anomaly detection algorithm running in a quality control line, a natural language processing layer that extracts signals from adverse event reports, a model that ranks patient eligibility for a trial — each of these is an AI decision point, and each carries its own explainability surface.

The explainability surface of a use case is the set of questions a regulator could reasonably ask about it. For a patient eligibility model, those questions include the features used, the threshold logic applied, the training data provenance, the validation approach, and the human override pathway. For a manufacturing quality model, they include the sensor inputs, the calibration record, the decision boundary, and the action taken when the threshold was crossed.

A useful mapping exercise assigns each AI decision point a regulatory exposure score. High-exposure points are those where a model output directly influences a regulated action — a release decision, a dosing recommendation, a protocol deviation flag. Medium-exposure points influence human judgment indirectly. Low-exposure points affect internal operations without touching a regulated artifact. This stratification allows teams to allocate explainability investment where the regulatory risk is highest, rather than applying uniform documentation effort across all AI outputs.

Designing Explainability at the Model Level

Model-level explainability is the foundation that all other documentation rests on. The choice of model architecture is itself a design decision with regulatory consequences. Interpretable models — logistic regression, decision trees, linear scoring functions — produce outputs that can be explained in plain language because their logic is inspectable. Black-box models — deep neural networks, ensemble methods with high cardinality — produce outputs that require post-hoc explanation techniques to make legible.

The decision to use a black-box model in a high-exposure use case is not automatically wrong, but it creates an obligation. That obligation is to deploy a validated explanation method alongside the model, to document the method's own limitations, and to demonstrate that the explanations it produces are faithful to the model's actual reasoning. SHAP values, LIME-based local approximations, and attention-weight visualization are the most commonly deployed methods, and each has documented failure modes that regulators may ask about.

Model documentation packages should capture, at minimum, the intended use statement, the training data description including any preprocessing transformations, the feature list with importance rankings, the validation dataset and performance metrics, the thresholds and their justification, and the known failure modes. This is not a one-time document — it is a living record that must be updated each time the model is retrained or its operating environment changes materially.

Version control for model artifacts is as important as version control for software code. A regulator reviewing an adverse event months after a model was updated needs to reconstruct exactly what version of the model was running at the time of the event. Organizations that store model weights, configuration files, and explanation method parameters in version-controlled repositories create this capability as a natural byproduct of good engineering practice. Those that treat model files as operational assets rather than regulated artifacts typically cannot reconstruct the decision environment retrospectively.

Building the Audit Trail Infrastructure

Explainability without an audit trail is just documentation that cannot be verified. The operational requirement goes beyond documenting what a model can do in principle — it extends to recording what the model actually did for each specific decision, at the time the decision was made. This is the distinction between model-level transparency and decision-level transparency, and regulators increasingly expect both.

A decision-level audit trail captures, for each model output, the input features and their values at the moment of inference, the model version and configuration hash, the output value and confidence interval if applicable, the explanation artifact generated for that output, and the human action taken in response. These records must be timestamped, immutable after creation, and retrievable by decision identifier. The retrieval requirement is non-trivial — organizations running models at high throughput can generate millions of decision records, and the infrastructure must support targeted queries without requiring manual data archaeology.

The storage architecture for audit trails in biotech AI must account for regulatory retention schedules. Clinical trial records in the US are typically subject to multi-year retention requirements, and AI decision records tied to clinical operations should be treated with the same lifecycle discipline. Cloud-based object storage with cryptographic integrity verification is a practical approach that most modern infrastructure patterns support.

Audit trail gaps are among the most common deficiencies cited in AI-related regulatory observations. A gap can occur because logging was not enabled for a particular model version, because log records were overwritten before they were exported, or because the logging schema did not capture the information a regulator subsequently asked for. The most resilient defense against gaps is designing the logging schema to regulatory standard before the system goes live, not after the first inquiry arrives.

Structuring Human Oversight Into the Decision Workflow

Regulatory confidence in AI systems rises substantially when there is a documented, functioning human oversight layer. This is not a concession to regulatory conservatism — it is sound operational design. A human oversight layer does two things simultaneously: it provides a circuit breaker for model errors, and it creates a named accountable party for each decision, which regulators require when regulated actions are at stake.

The design of human oversight must be specific to the decision type. For a model that flags manufacturing deviations, oversight means a qualified person reviews the flag, applies their judgment, and records their conclusion before any downstream action is taken. For a model that ranks trial candidates, oversight means a clinical operations lead reviews the ranking, applies inclusion criteria that the model does not fully encode, and documents the basis for any departure from the model's order.

The oversight record must be captured in the same audit infrastructure as the model record. A common failure pattern is organizations that build excellent model-level logging but record human decisions in a separate system — a paper form, an email thread, a spreadsheet — that cannot be linked back to the specific model output it reviewed. The linkage between model decision and human review is itself a regulated artifact, and it should be treated accordingly.

Oversight thresholds matter as much as oversight existence. A human reviewer who sees five hundred model flags per day and has thirty seconds per review is not providing meaningful oversight, regardless of what the process document says. Calibrating the volume of model output to the realistic capacity of the review function is an operational design requirement that regulators have begun to probe directly. For a deeper treatment of how to set these thresholds in practice, the resource at https://www.labarna.ai/blog/12-thresholds-that-should-trigger-human-escalation-for-saudi-telecom-ope offers a transferable methodology applicable well beyond its original vertical context.

Preparing Regulatory Submissions That Address AI Logic

A submission that incorporates an AI-assisted decision — whether it is a 510(k), a biologics license application component, or a site audit package — must address the AI logic in a structured section that regulators can navigate without specialized technical knowledge. The technical depth belongs in an appendix or module. The main submission body should convey the system's intended use, the oversight structure, the validation approach, and the error management pathway in language accessible to a reviewer with a regulatory science background but not necessarily a machine learning background.

This means translating model concepts into regulatory language. A confidence score becomes a probability of correct classification with a documented operating range. A feature importance ranking becomes a description of the evidence variables the system considers and their relative contribution to the output. A drift detection alarm becomes a documented process for identifying when the system's operating environment has changed materially and what action the organization takes when that occurs.

Submission narratives should anticipate the most common regulatory questions about AI systems. These include: How was the training data collected and verified? How was the validation dataset separated from training data? What performance was observed on the validation set? What is the expected performance degradation profile as the model ages? What triggers retraining? Who is responsible for the system's performance over time? Organizations that answer these questions proactively, before they are asked, create a perception of rigor and operational control that positively influences the review dynamic.

The submissions team and the data science team must co-own the AI section of any submission package. When these teams operate independently, the regulatory narrative and the technical reality frequently diverge in ways that create questions during review. A joint review process, with explicit sign-off from the model owner on the accuracy of every statement in the regulatory narrative, is the minimum governance standard for submissions involving AI.

Handling Regulator Questions During Review

Even well-prepared submissions receive questions. When a regulator sends a deficiency letter or an information request touching on AI system logic, the response process is distinct from the ordinary response workflow because the underlying evidence is technical. The response team must include someone with direct knowledge of the model architecture and training history, not just the regulatory affairs function.

Responses to AI-related questions should follow a clear structure: restate the question to confirm shared understanding, provide the specific technical answer with supporting artifacts, explain the significance of that answer in regulatory terms, and describe any additional controls the organization has implemented or is implementing in response to the concern the question reveals. This structure converts a technical response into a regulatory narrative.

The artifacts attached to responses should come directly from the version-controlled model repository and the audit trail infrastructure. Documents that appear to have been created specifically in response to the question, rather than retrieved from ongoing operational records, undermine the appearance of genuine operational discipline. Regulators are experienced readers of organizational documentation, and the difference between a retrieved record and a retroactively constructed one is usually visible.

Organizations that receive questions suggesting a fundamental concern about the AI system's transparency — rather than a routine clarification request — should consider requesting a pre-submission meeting or a Type B meeting to align with the relevant FDA division before submitting a formal response. These meetings, while resource-intensive, allow organizations to understand the specific concern before committing to a written response position.

Deploying Sovereign AI Infrastructure to Support Compliance

The architecture of the AI infrastructure itself determines whether these explainability requirements are practically achievable. Organizations running AI on third-party platforms they do not control face a structural problem: the model artifacts, training records, and inference logs may sit in systems whose data policies, retention schedules, and access controls are set by the vendor rather than the organization. When a regulator asks for a model configuration file or an inference log from eighteen months ago, the answer "our vendor would need to provide that" is not an acceptable submission response.

Sovereign AI infrastructure — where the organization owns and controls the model code, weights, configuration, and all operational logs — eliminates this dependency. The explainability artifacts are in-house, version-controlled, and retrievable on demand. This is a material advantage in any regulatory context, not a theoretical one.

Labarna AI's Ghost Architecture model addresses this directly: clients own all source code, agents, data, and IP, with no shared infrastructure that could create a data access or retention gap at a critical regulatory moment. For a biotech firm building agentic systems to support clinical operations or manufacturing quality, this ownership structure means the compliance record is always in the firm's possession. Deployments start in the low tens of thousands for focused builds, which makes sovereign infrastructure economically accessible at a stage when many firms would otherwise default to a SaaS dependency. More context on how sovereign infrastructure supports regulated-industry compliance is available at https://www.tfsfventures.com/blog/deploying-ai-agents-in-regulated-industries-a-compliance-playbook.

Creating a Continuous Monitoring Program

Explainability is not a point-in-time achievement — it is an ongoing operational state. A model that was explainable and well-documented at deployment can become opaque over time if its operating environment changes, its inputs drift, or undocumented updates are applied. The regulatory standard implies that the organization maintains its ability to explain AI decisions at any point during the system's operational life, not just at the moment of submission.

A continuous monitoring program for AI explainability includes several components. Input monitoring detects when the distribution of data entering the model has shifted materially from the training distribution — a common early signal that model reliability may be degrading. Output monitoring detects when the model's output distribution changes without a corresponding change in input, which can indicate model decay or an integration issue. Explanation monitoring detects when the explanations generated by a post-hoc method become inconsistent or implausible, which can indicate that the explanation method is no longer faithfully representing the model's reasoning.

Each monitoring component should have a documented response procedure. When an input drift alarm fires, what does the organization do? Who reviews it? What is the threshold for pausing the system versus logging the event for investigation? These procedures must be written before the system goes live and should be updated based on the organization's actual operational experience with the system over time.

Monitoring records belong in the same controlled documentation environment as the original model validation records. A regulator auditing a site that uses AI in manufacturing quality should be able to pull not just the original validation package but the complete monitoring history — every alarm, every investigation, every decision to continue or suspend system operation. The monitoring program is the evidence that the organization has sustained operational control over the system throughout its lifecycle.

Preparing Teams for Regulatory Interactions

Technical preparation matters, but so does the human readiness of the teams who will speak to regulators about AI systems. A regulatory affairs professional who cannot explain what a confidence score means, or a data scientist who cannot articulate the regulatory significance of a drift event, creates gaps that show up in meetings and inspection responses.

Cross-functional preparation for AI regulatory interactions should be built into the operating model, not treated as a pre-inspection sprint. Data scientists who work on regulated AI systems should understand the regulatory framework their work operates within — including the FDA's published guidance documents, the expectations for predicate software documentation, and the principles governing software validation in regulated environments. Regulatory professionals who oversee AI submissions should have enough technical literacy to critically read a model validation report and identify gaps before a regulator does.

Tabletop exercises — where the team walks through a simulated regulatory inquiry, with specific questions and simulated evidence retrieval — are among the most effective preparation tools. These exercises surface the gaps between what the documentation says and what the operational system actually supports before those gaps become regulatory observations.

The teams conducting these exercises should include a member who can play the regulator's role credibly, pushing for specificity and challenging vague answers. Organizations that discover under simulated pressure that their audit trail is incomplete or their explanation artifacts are missing have the opportunity to correct the gap on their own schedule. The investment in that exercise returns multiples when the real interaction occurs.

Governing AI Model Changes After Initial Approval

Post-approval governance is where many biotech firms' AI compliance programs break down. A model approved as part of a submission record has a documented configuration. Any subsequent change to that model — even a retraining run on expanded data with the same architecture — creates a new configuration that must be assessed against the approved record. The questions are whether the change constitutes a significant modification, whether it requires a new submission or only a record update, and how the explanation artifacts must be updated to reflect the new configuration.

The FDA's framework for predetermined change control plans, introduced in its AI/ML guidance, provides a pathway for managing planned model updates within a pre-approved scope. Organizations that define their expected update types in advance — and document the evidence standard they will apply to each type — can manage ongoing model evolution without triggering a full resubmission for each iteration.

Change governance for AI systems should be owned by a cross-functional committee that includes regulatory affairs, data science, quality, and the business function the model supports. Changes should go through a documented impact assessment before implementation. The impact assessment asks: does this change affect the regulatory characterization of the system? Does it fall within the predetermined change control plan? Does it require notification to the regulator before implementation? These questions, answered in writing before every change, create the governance record that demonstrates ongoing operational discipline.

Agentic AI and the Next Frontier of Regulatory Explainability

Biotech organizations are beginning to deploy agentic AI — systems where multiple AI components interact autonomously, executing sequences of actions rather than producing a single output for human review. Agentic AI deployment introduces a new explainability dimension: not just why did the model produce this output, but why did the system take this sequence of actions, and at what point in the sequence was a human able to intervene.

Agentic architectures generate explainability records at the orchestration level, not just the model level. Each agent action must be logged, each agent-to-agent communication must be traceable, and the decision logic that triggered each action must be reconstructable. For biotech applications — a multi-step compound screening workflow, an automated regulatory document assembly pipeline, an autonomous trial protocol deviation monitor — this orchestration-level transparency is the new frontier of compliance documentation.

Labarna AI's sovereign production intelligence model is built specifically for this production-grade agentic context. Its Pulse engine and Ghost Architecture approach ensure that every agent action within a deployed system is owned by the client, logged in controlled infrastructure, and retrievable for regulatory purposes. For organizations asking whether a specific AI deployment partner has the operational depth to support regulated-industry compliance, the verifiable registration under RAKEZ License 47013955 and the founder's 27 years in payments and software provide a concrete answer to questions about Labarna AI's legitimacy. For the broader agentic compliance methodology, https://www.tfsfventures.com/blog/exception-handling-for-ai-agents-in-biotech provides a practical treatment of how exception handling in agentic biotech systems should be structured.

Building a Regulatory-Ready AI Governance Program

All of the preceding elements — model documentation, audit trail infrastructure, human oversight, submission preparation, post-approval change governance, continuous monitoring, and agentic transparency — require a governance program to hold them together. Without explicit governance ownership, these functions operate in silos and the compliance record becomes fragmented.

A regulatory-ready AI governance program has a named owner at the leadership level. That owner chairs a cross-functional AI governance committee that meets on a defined cadence, reviews the organization's AI risk register, approves new AI deployments in regulated contexts, and provides oversight of the monitoring program. The committee is not a bottleneck — it is a decision authority for questions that cross functional boundaries.

The risk register is the central document. It lists every AI system operating in a regulated context, its regulatory exposure level, its current compliance status, its monitoring status, and any open issues. The register should be reviewed at every committee meeting and updated whenever a new system is deployed or an existing system's status changes.

Labarna AI's approach to agentic AI deployment — spanning 21 verticals including biotech and life sciences — is designed to integrate with this kind of governance program. The 19-question operational assessment that initiates every engagement directly surfaces the governance gaps that need to be addressed before a production system goes live. For firms evaluating agentic AI deployment options and asking whether the infrastructure can support the compliance requirements described throughout this article, the Operational Intelligence Diagnostic delivers a deployment blueprint within 24 to 48 hours — at no cost, and grounded in the organization's specific operational context rather than a generic template.

About Labarna AI

Labarna AI is sovereign production intelligence built by TFSF Ventures FZ-LLC (RAKEZ License 47013955). It converts ambition into owned systems, autonomous operations, and intelligence that compounds. Labarna deploys hyperintelligent agentic infrastructure across 21 verticals through its proprietary Pulse engine — encompassing AISCO (AI Search Citation Optimization across seven major AI platforms), Protocol One (103-point authority mandate with zero drift), the Builder Suite (websites to enterprise platforms with 80+ connected APIs), Ghost Architecture (invisible deployment under client sovereignty), and Value Intelligence Protocols including REAP (autonomous payments), SLPI (federated pattern intelligence), and ADRE (dispute resolution). AI was built to answer — Labarna was built to act.

Get Started with Labarna AI

Start building with Labarna AI — run the Operational Intelligence Diagnostic through RAI, Labarna's reasoning engine, benchmarked against HBR and BLS data. Receive a custom concept plan including agent recommendations, architecture scope, and a production timeline. Enter the system at labarna.ai.

Originally published at https://www.labarna.ai/blog/how-us-biotech-firms-can-explain-ai-decisions-to-regulators

Written by Labarna AI Research